Marmesinacetat | 64911-87-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: Marmesinacetat
• 英文别名: (+)-O-Acetyl-marmesin；marmesin acetate；2-[(2S)-7-oxo-2,3-dihydrofuro[3,2-g]chromen-2-yl]propan-2-yl acetate
• CAS: 64911-87-1
• 化学式: C₁₆H₁₆O₅
• 分子量: 288.3
• InChiKey: XBEFQTHUADKZEH-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (S)-2-(1-(beta-D-吡喃葡萄糖基氧基)-1-甲基乙基)-2,3-二氢-7H-呋喃并(3,2-g)(1)苯并吡喃-7-酮 在 盐酸 、 sodium acetate 作用下， 生成 Marmesinacetat
  参考文献：
  名称：

  Notes - Ammajin, a New Constituent of Ammi Majus (L.)

  摘要：

  DOI：

  10.1021/jo01105a632

文献信息

• Isolation of Marmesin from the Fruits of Ammi majus Linn.
  作者：EFFAT A. ABU-MUSTAFA、NASRY BADRAN、M. B. E. FAYEZ、N. A. STARKOWSKY

  DOI：10.1038/182054a0

  日期：1958.7

  Ammi majus Linn. (Umbelliferae) is a wild plant which grows in Egypt, producing fruits reputed for their use in the treatment of leucodermia. They are mentioned in old Arab literature1, and their value has recently been established by clinical investigations2. In 1947, Fahmy and Schönberg and their associates3 reported the isolation of three crystalline compounds—ammoidin, ammidin and majudin—from the petroleum ether extract of the fruits. These compounds, or in any event the first two, were shown to be efficacious in the treatment of leucodermia4–6 and are produced commercially (by The Memphis Chemical Co., Zeitoun, Cairo) for that purpose. Shortly afterwards, Schönberg5,7 demonstrated that ammoidin and ammidin are actually the furocoumarins xanthotoxin8 and imperatorin9 respectively, and majudin was shown to be bergapten4.

  Ammi majus Linn.（伞形科）是一种野生植物，生长在埃及，其果实因治疗白皮病而闻名。 它们在古老的阿拉伯文献中有所提及1，其价值最近通过临床研究得以证实2。 1947年，Fahmy和Schoenberg及其同事3报告从果实的石油醚提取物中分离出三种结晶化合物——ammoidin、ammidin和majudin。 这些化合物，或至少前两种，被证明对治疗白皮病有效4-6，并已用于商业生产（由开罗Zeitoun的孟菲斯化学公司生产）。 不久之后，Schoenberg5,7证明ammoidin和ammidin实际上分别是呋喃香豆素黄酮毒素8和imperatorin9，而majudin被证明是bergapten4。
• On the Constitution of the Active Principles Isolated from the Matured Bark of <i>Aegle marmelos</i>, Correâ
  作者：Asima. Chatterjee、Sudhangsu Sekhar. Mitra

  DOI：10.1021/ja01170a062

  日期：1949.2
• COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING
  申请人：Orlow Seth J.

  公开号：US20110190229A1

  公开（公告）日：2011-08-04

  A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.
• COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF
  申请人：ORLOW Seth J.

  公开号：US20120220545A1

  公开（公告）日：2012-08-30

  Provided are coumarin compounds of formula I, for example, robustic acid methyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. wherein R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.
• US8563754B2
  申请人：——

  公开号：US8563754B2

  公开（公告）日：2013-10-22